title: Questions about adjuvant trastuzumab still remain.
authors.affiliation: Health Economics and Decision Science, School of Health and Related Research, University of Sheffield, Sheffield S1 4DA, UK. d.hind@sheffield.ac.uk
authors.forename: Daniel
authors.initials: D
authors.lastname: Hind
authors.forename: Hazel
authors.initials: H
authors.lastname: Pilgrim
authors.forename: Sue
authors.initials: S
authors.lastname: Ward
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D001943:Breast Neoplasms / Q000188:drug therapy*; D017024:Chemotherapy, Adjuvant / Q000009:adverse effects; D018572:Disease-Free Survival; D005260:Female; D006333:Heart Failure / Q000139:chemically induced*; D006801:Humans; D019057:Quality-Adjusted Life Years; D016032:Randomized Controlled Trials as Topic; D000068878:Trastuzumab
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068878:Trastuzumab